BACKGROUND: Rifampin (RIF) is the most important first-line antituberculosis drug, and resistance to this drug may result in treatment failures. We evaluated the diagnostic performances of recently introduced, molecular assays for the detection of RIF resistance. METHODS: A total of 100 isolates (50 RIF resistant and 50 RIF susceptible) were studied. Their RIF resistances were determined by conventional drug-susceptibility test. These results were compared with those of three molecular assays: Xpert MTB/RIF assay (MTB is Mycobacterium tuberculosis), Sacace MTB Real-TM resistance, and AdvanSure MDR-TB GenoBlot assay (MDR is multidrug resisitant). RESULTS: Sensitivities for RIF resistance detection of Xpert MTB/RIF assay, Sacace MTB Real-TM resistance, and Advansure GenoBlot assay were 94.0%, 91.8%, and 84.0%, respectively. Their specificities for RIF resistance detection were all 100%. CONCLUSION: Three molecular assays for the detection of RIF resistance have various performances. Xpert MTB/RIF assay shows the highest sensitivity among the three molecular assays and can be an effective choice in clinical laboratories.
BACKGROUND: Rifampin (RIF) is the most important first-line antituberculosis drug, and resistance to this drug may result in treatment failures. We evaluated the diagnostic performances of recently introduced, molecular assays for the detection of RIF resistance. METHODS: A total of 100 isolates (50 RIF resistant and 50 RIF susceptible) were studied. Their RIF resistances were determined by conventional drug-susceptibility test. These results were compared with those of three molecular assays: Xpert MTB/RIF assay (MTB is Mycobacterium tuberculosis), Sacace MTB Real-TM resistance, and AdvanSure MDR-TB GenoBlot assay (MDR is multidrug resisitant). RESULTS: Sensitivities for RIF resistance detection of Xpert MTB/RIF assay, Sacace MTB Real-TM resistance, and Advansure GenoBlot assay were 94.0%, 91.8%, and 84.0%, respectively. Their specificities for RIF resistance detection were all 100%. CONCLUSION: Three molecular assays for the detection of RIF resistance have various performances. Xpert MTB/RIF assay shows the highest sensitivity among the three molecular assays and can be an effective choice in clinical laboratories.
Authors: Grant Theron; Jonny Peter; Richard van Zyl-Smit; Hridesh Mishra; Elizabeth Streicher; Samuel Murray; Rodney Dawson; Andrew Whitelaw; Michael Hoelscher; Surendra Sharma; Madhukar Pai; Robin Warren; Keertan Dheda Journal: Am J Respir Crit Care Med Date: 2011-04-14 Impact factor: 21.405
Authors: Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins Journal: N Engl J Med Date: 2010-09-01 Impact factor: 91.245
Authors: Danica Helb; Martin Jones; Elizabeth Story; Catharina Boehme; Ellen Wallace; Ken Ho; JoAnn Kop; Michelle R Owens; Richard Rodgers; Padmapriya Banada; Hassan Safi; Robert Blakemore; N T Ngoc Lan; Edward C Jones-López; Michael Levi; Michele Burday; Irene Ayakaka; Roy D Mugerwa; Bill McMillan; Emily Winn-Deen; Lee Christel; Peter Dailey; Mark D Perkins; David H Persing; David Alland Journal: J Clin Microbiol Date: 2009-10-28 Impact factor: 5.948
Authors: Catharina C Boehme; Mark P Nicol; Pamela Nabeta; Joy S Michael; Eduardo Gotuzzo; Rasim Tahirli; Ma Tarcela Gler; Robert Blakemore; William Worodria; Christen Gray; Laurence Huang; Tatiana Caceres; Rafail Mehdiyev; Lawrence Raymond; Andrew Whitelaw; Kalaiselvan Sagadevan; Heather Alexander; Heidi Albert; Frank Cobelens; Helen Cox; David Alland; Mark D Perkins Journal: Lancet Date: 2011-04-18 Impact factor: 79.321